The estimated Net Worth of Nancy Leaming is at least $12.2 Milion dollars as of 3 March 2017. Ms. Leaming owns over 10,000 units of Biogen Inc stock worth over $10,585,217 and over the last 21 years she sold BIIB stock worth over $1,176,826. In addition, she makes $421,333 as Independent Director at Biogen Inc.
Nancy has made over 25 trades of the Biogen Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently she exercised 10,000 units of BIIB stock worth $328,200 on 3 March 2017.
The largest trade she's ever made was exercising 36,810 units of Biogen Inc stock on 3 March 2017 worth over $192,148. On average, Nancy trades about 4,737 units every 73 days since 2004. As of 3 March 2017 she still owns at least 53,168 units of Biogen Inc stock.
You can see the complete history of Ms. Leaming stock trades at the bottom of the page.
Nancy L. Leaming is an Independent Director of Biogen Inc. Ms. Leaming has been an independent consultant since 2005. From 2003 to 2005 she served as the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. From 1986 to 2003 Ms. Leaming served in several executive positions at Tufts Health Plan, including President, Chief Operating Officer and Chief Financial Officer.
As the Independent Director of Biogen Inc, the total compensation of Nancy Leaming at Biogen Inc is $421,333. There are 13 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Nancy Leaming is 71, she's been the Independent Director of Biogen Inc since 2008. There are 1 older and 23 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Nancy's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner a Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: